Last reviewed · How we verify
NCT03851055
Zinc Supplementation in Patients With β-Thalassemia Major Complicated With Diabetes Mellitus
Phase 3 trial testing Zinc in Beta-thalassemia Major Complicated With Diabetes in 80 participants. Completed in 28 August 2018.
10 July 2018
Quick facts
| Lead sponsor | Ain Shams University |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 1 August 2017 |
| Primary completion | 10 July 2018 |
| Estimated completion | 28 August 2018 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Zinc — full drug profile →
Conditions studied
- Beta-thalassemia Major Complicated With Diabetes — all drugs for Beta-thalassemia Major Complicated With Diabetes →
Sponsor
Ain Shams University
Who can join
Adults 10 to 18, any sex, with Beta-thalassemia Major Complicated With Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Beta-thalassemia represents a group of recessive inherited hemoglobin disorders characterized by reduced synthesis of β-globin chain. The homozygous state (β-thalassemia major) "TM" results in severe anemia, which needs regular blood transfusion . The life expectancy in patients with TM has increased due to therapeutically management, such as frequent transfusion, desferal administration and bone marrow transplantation. Diabetes is clinically characterized by hyperglycemia due to either low circulating concentrations of, or decreased sensitivity to, insulin. Patients with TM typically exhibit β-cell or insulin insufficiency, and may develop diabetes due to toxic levels of iron in their pancreas, one of the strongest predictors of β-cell destruction. By contrast, hyperinsulinemia, secondary to insulin resistance, with normal glucose tolerance has also been observed. The pathogenic mechanisms leading from siderosis to diabetes are poorly understood.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03851055
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Zinc
Trials testing the same drug.
- NCT06664008 — The Effect of Probiotic and Zinc Supplementation in Patients With Gastroesophageal Reflux Disease · Phase 4 · not yet recruiting
- NCT06540209 — Comparison of Effectiveness of Zinc Supplementation With ORS and Bacillus Clausii Versus Zinc With ORS and Saccharomyces · NA · completed
- NCT05785013 — The Impact of Preoperative Supplementation of Zinc · NA · completed
- NCT05212480 — Evaluation of the Efficacy and Safety of Zinc in Viral Infections · NA · completed
- NCT05453227 — Zinc Containing Vaginal Topical " Suppository " · Phase 1, PHASE2 · completed
Other Ain Shams University trials
Trials by the same sponsor.
- NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
- NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
- NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
- NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
- NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03851055 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
- Last refreshed: 25 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03851055.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing